Phase III trial of ipilimumab in metastatic melanoma demonstrates improvement in survival

被引：0
|
作者：
不详
机构：
来源：
FUTURE ONCOLOGY | 2010年 / 6卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1208 / 1208
页数：1
相关论文
共 50 条
  • [31] Ipilimumab attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
    Peggs, Karl S.
    Quezada, Sergio A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (11) : 1697 - 1701
  • [32] Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial
    Baurain, Jean-Francois
    Smylie, Michael
    Ascierto, Paolo Antonio
    Roman, Laslo
    Houston, Stephen
    Konto, Cyril
    Chin, Kevin M.
    Chen, Tai-Tsang
    Francis, Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Ipilimumab with fotemustine in metastatic melanoma
    Garbe, Claus
    LANCET ONCOLOGY, 2012, 13 (09): : 851 - 852
  • [34] Ipilimumab for advanced metastatic melanoma
    Starz, Hans
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (08) : 981 - 982
  • [35] Ipilimumab (Yervoy) for Metastatic Melanoma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1367): : 51 - 52
  • [36] Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma A Randomized Clinical Trial
    Hodi, F. Stephen
    Lee, Sandra
    McDermott, David F.
    Rao, Uma N.
    Butterfield, Lisa H.
    Tarhini, Ahmad A.
    Leming, Philip
    Puzanov, Igor
    Shin, Donghoon
    Kirkwood, John M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (17): : 1744 - 1753
  • [37] Combined High Dose Radiation and Ipilimumab in Metastatic Melanoma, a Phase I Dose Escalation Trial.
    De Wolf, K.
    Kruse, V.
    Brochez, L.
    Sundahl, N.
    Van Gele, M.
    Speeckaert, R.
    Ost, P.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S5 - S5
  • [38] A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.
    Di Giacomo, Anna Maria
    Annesi, Diego
    Ascierto, Paolo Antonio
    Calabro, Luana
    Chiarion-Sileni, Vanna
    Danielli, Riccardo
    Del Vecchio, Michele
    Ferraresi, Virginia
    Ferrucci, Pier Francesco
    Fonsatti, Ester
    Guida, Michele
    Giannarelli, Diana
    Guidoboni, Massimo
    Mandala, Mario
    Quaglino, Pietro
    Queirolo, Paola
    Maccalli, Cristina
    Parmiani, Giorgio
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Efficacy and Safety of Ipilimumab in Patients with Metastatic Melanoma: Summary of Results from two Ipilimumap Phase III Studies
    Schadendorf, D.
    Becker, J.
    Garbe, C.
    Hauschild, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 (09): : 778 - 779
  • [40] A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma
    Hodi, F. S.
    Friedlander, P. A.
    Atkins, M. B.
    McDermott, D. F.
    Lawrence, D. P.
    Ibrahim, N.
    Wu, X.
    Zhou, J.
    Giobbie-Hurder, A.
    Murphy, G.
    Hollman, T.
    Velazquez, E.
    Russell, S.
    Dipiro, P.
    Yap, J. T.
    Van den Abbeele, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345